@Article{096504021X16184815905096,
AUTHOR = {Chunmou Li, Xiaomin Peng, Chuchu Feng, Xilin Xiong, Jianxin Li, Ning Liao, Zhen Yang, Aiguo Liu, Pingping Wu, Xuehong Liang, Yunyan He, Xin Tian, Yunbi Lin, Songmi Wang, Yang Li},
TITLE = {Excellent Early Outcomes of Combined Chemotherapy With  Arsenic Trioxide for Stage 4/M Neuroblastoma in Children:  A Multicenter Nonrandomized Controlled Trial},
JOURNAL = {Oncology Research},
VOLUME = {28},
YEAR = {2020},
NUMBER = {7-8},
PAGES = {791--800},
URL = {http://www.techscience.com/or/v28n7-8/48468},
ISSN = {1555-3906},
ABSTRACT = {This nonrandomized, multicenter cohort, open-label clinical trial evaluated the efficacy and safety of combined 
chemotherapy with arsenic trioxide (ATO) in children with stage 4/M neuroblastoma (NB). We enrolled patients 
who were newly diagnosed with NB and assessed as stage 4/M and received either traditional chemotherapy 
or ATO combined with chemotherapy according to their own wishes. Twenty-two patients were enrolled in 
the trial group (ATO combined with chemotherapy), and 13 patients were enrolled in the control group (traditional chemotherapy). Objective response rate (ORR) at 4 weeks after completing induction chemotherapy was 
defined as the main outcome, and adverse events were monitored and graded in the meantime. Data cutoff date 
was December 31, 2019. Finally, we found that patients who received ATO combined with chemotherapy had 
a significantly higher response rate than those who were treated with traditional chemotherapy (ORR: 86.36% 
vs. 46.16%, <i>p</i> = 0.020). Reversible cardiotoxicity was just observed in three patients who were treated with 
ATO, and no other differential adverse events were observed between the two groups. ATO combined with 
chemotherapy can significantly improve end-induction response in high-risk NB, and our novel regimen is well 
tolerated in pediatric patients. These results highlight the superiority of chemotherapy with ATO, which creates 
new opportunity for prolonging survival. In addition, this treatment protocol minimizes therapeutic costs compared with anti-GD2 therapy, MIBG, and proton therapy and can decrease the burden to families and society. 
However, we also need to evaluate more cases to consolidate our conclusion.},
DOI = {10.3727/096504021X16184815905096}
}